PMID- 35068928
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 16
DP  - 2022
TI  - Patient and Caregiver Preferences for First-Line Treatments of Metastatic 
      Non-Small Cell Lung Cancer: A Discrete Choice Experiment.
PG  - 123-135
LID - 10.2147/PPA.S338840 [doi]
AB  - PURPOSE: The approval of immune checkpoint inhibitors for metastatic 
      non-small-cell lung carcinomas (mNSCLC) treatment has presented more care 
      options. Therefore, it is important to identify the benefit-risk trade-offs 
      patients and caregivers are willing to make among potential treatment options. 
      This study quantified the preferences of patients and caregivers for attributes 
      of mNSCLC treatment. METHODS: Patients with mNSCLC and caregivers completed an 
      online survey assessing preferences using a discrete choice experiment. 
      Respondents chose between hypothetical treatment profiles, with varying levels 
      for 7 attributes associated with first-line treatment, including overall survival 
      (OS), progression-free survival, select adverse events (AEs), and regimen 
      (caregivers). Hierarchical Bayesian modeling was used to estimate attribute-level 
      preference weights. RESULTS: Patients (n = 308) and caregivers (n = 166) most 
      valued increasing OS from 11 to 30 months, followed by decreasing the risk of a 
      serious AE (grade 3/4) that may lead to hospitalization from 70% to 18%. These 
      attributes were over twice as important to both sets of respondents as the other 
      attributes measured. Patients and caregivers would accept increases in the risks 
      of a serious AE (grade 3/4) from 18% to 70% and all grades nausea from 10% to 69% 
      if OS increased by 16.8 and 4.0 months, respectively. The least valued attributes 
      were all grades of pneumonitis (patients) and all grades of skin rash 
      (caregivers). CONCLUSION: Patients and caregivers are willing to make trade-offs 
      between efficacy and toxicity and may require up to 1.5 years of increased OS to 
      accept a higher risk of AEs. These results can provide guidance to oncologists 
      when engaging in shared-decision making discussions.
CI  - (c) 2022 Yong et al.
FAU - Yong, Candice
AU  - Yong C
AUID- ORCID: 0000-0002-9264-0720
AD  - AstraZeneca, Gaithersburg, MD, USA.
FAU - Cambron-Mellott, M Janelle
AU  - Cambron-Mellott MJ
AUID- ORCID: 0000-0003-0061-104X
AD  - Cerner Enviza, Malvern, PA, USA.
FAU - Seal, Brian
AU  - Seal B
AUID- ORCID: 0000-0002-4914-6161
AD  - AstraZeneca, Gaithersburg, MD, USA.
FAU - Will, Oliver
AU  - Will O
AUID- ORCID: 0000-0002-6514-8298
AD  - Cerner Enviza, Malvern, PA, USA.
FAU - Maculaitis, Martine C
AU  - Maculaitis MC
AUID- ORCID: 0000-0001-8388-5315
AD  - Cerner Enviza, Malvern, PA, USA.
FAU - Clapp, Kelly
AU  - Clapp K
AD  - Cerner Enviza, Malvern, PA, USA.
FAU - Mulvihill, Emily
AU  - Mulvihill E
AD  - Cerner Enviza, Malvern, PA, USA.
FAU - Cotarla, Ion
AU  - Cotarla I
AUID- ORCID: 0000-0002-8986-3616
AD  - AstraZeneca, Gaithersburg, MD, USA.
FAU - Mehra, Ranee
AU  - Mehra R
AUID- ORCID: 0000-0003-2477-9584
AD  - University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, 
      MD, USA.
LA  - eng
PT  - Journal Article
DEP - 20220115
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC8769053
OTO - NOTNLM
OT  - immune checkpoint inhibitors
OT  - metastases
OT  - non-small-cell lung carcinomas
OT  - overall survival
OT  - patient preference
OT  - toxicities
COIS- Candice Yong and Brian Seal were employees and shareholders of AstraZeneca at the 
      time of study conduct. Ion Cotarla is an employee and shareholder of AstraZeneca. 
      M. Janelle Cambron-Mellott, Oliver Will, Martine C. Maculaitis, Kelly Clapp, and 
      Emily Mulvihill are employees of Cerner Enviza, which received funding from 
      AstraZeneca for conducting the study and analysis and for manuscript preparation. 
      Ranee Mehra is an employee of University of Maryland Marlene and Stewart 
      Greenebaum Cancer Center, which received research funding from AstraZeneca for 
      consulting on the study. Ranee Mehra's institution has also received research 
      funding outside of this work from AstraZeneca and Merck, and she has received 
      consulting fees from Rakuten Medical, outside of this work. The authors report no 
      other conflicts of interest in this work.
EDAT- 2022/01/25 06:00
MHDA- 2022/01/25 06:01
PMCR- 2022/01/15
CRDT- 2022/01/24 08:47
PHST- 2021/09/11 00:00 [received]
PHST- 2021/12/15 00:00 [accepted]
PHST- 2022/01/24 08:47 [entrez]
PHST- 2022/01/25 06:00 [pubmed]
PHST- 2022/01/25 06:01 [medline]
PHST- 2022/01/15 00:00 [pmc-release]
AID - 338840 [pii]
AID - 10.2147/PPA.S338840 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2022 Jan 15;16:123-135. doi: 10.2147/PPA.S338840. 
      eCollection 2022.